Future Neurology最新文献

筛选
英文 中文
Dendritic polyglycerols are modulators of microglia-astrocyte crosstalk 树突状聚甘油是小胶质细胞-星形胶质细胞串扰的调节剂
IF 1.3
Future Neurology Pub Date : 2019-11-01 DOI: 10.2217/fnl-2019-0008
D. Maysinger, Mélanie Lalancette–Hébert, Jeff Ji, K. Jabbour, J. Dernedde, K. Silberreis, R. Haag, J. Kriz
{"title":"Dendritic polyglycerols are modulators of microglia-astrocyte crosstalk","authors":"D. Maysinger, Mélanie Lalancette–Hébert, Jeff Ji, K. Jabbour, J. Dernedde, K. Silberreis, R. Haag, J. Kriz","doi":"10.2217/fnl-2019-0008","DOIUrl":"https://doi.org/10.2217/fnl-2019-0008","url":null,"abstract":"Aim: To determine the ability of sulfated dendritic polyglycerols (dPGS) to modulate neuroglia activation challenged with lipopolysaccharide (LPS). Materials & methods: Microglia/astrocyte activation in vivo was determined in transgenic animals expressing TLR2-/GFAP-luciferase reporter. Mechanisms implicated in microglia-astrocyte crosstalk were studied in primary mouse brain cultures. Results & discussion: dPGS significantly reduced microglia activation in vivo, and decreased astrocytic LCN2 production. Activated microglia are necessary for astrocyte stimulation and increase in LCN2 abundance. LCN2 production in astrocytes involves signaling via toll-like receptor 4, activation of NF-κB, IL6 and enhancement of reactive oxygen species. Conclusion: dPGS are powerful modulators of microglia-astrocyte crosstalk and LCN2 abundance; dPGS are promising anti-inflammatory dendritic nanostructures.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fnl-2019-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45348300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
The prevalence of delirium in patients in Iran: a systematic review and meta-analysis 伊朗患者谵妄患病率的系统综述和荟萃分析
IF 1.3
Future Neurology Pub Date : 2019-11-01 DOI: 10.2217/fnl-2018-0044
E. Khalighi, A. Tarjoman, A. Abdi, M. Borji
{"title":"The prevalence of delirium in patients in Iran: a systematic review and meta-analysis","authors":"E. Khalighi, A. Tarjoman, A. Abdi, M. Borji","doi":"10.2217/fnl-2018-0044","DOIUrl":"https://doi.org/10.2217/fnl-2018-0044","url":null,"abstract":"Aim: The first systematic review and meta analysis investigating the prevalence of delirium in Iran and the importance of delirium in the health status of patients. Method: This study is a review article to determine the overall prevalence of delirium in patients admitted to the hospitals in Iran, with search time frame to 12 October 2000–12 October 2018. The study examined the prevalence of delirium in general wards and ICUs of Iran according to published article in domestic and foreign journals. The methodological quality of the papers was based on a tool used in previous studies. Data was analyzed using comprehensive meta-analysis (CMA) software. Findings: The findings showed the prevalence of delirium in hospitalized patients in Iran is 21.8% (CI: 17.5–27.5%). The prevalence of delirium in hospitalized patients in Iran based on the hospitalization in ICU is 24.7% (CI: 18.1–32.7%) and in the general ward is 17.5% (CI: 13.6–22.3%). Conclusion: Due to the relatively high prevalence of delirium in patients admitted to hospitals in Iran, prevention is necessary to reduce the incidence of delirium.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fnl-2018-0044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42481613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Teaching an old drug new tricks: repositioning strategies for spinal muscular atrophy 教老药新把戏:脊髓性肌肉萎缩的重新定位策略
IF 1.3
Future Neurology Pub Date : 2019-08-01 DOI: 10.2217/FNL-2019-0006
Joseph M. Hoolachan, Emma R Sutton, M. Bowerman
{"title":"Teaching an old drug new tricks: repositioning strategies for spinal muscular atrophy","authors":"Joseph M. Hoolachan, Emma R Sutton, M. Bowerman","doi":"10.2217/FNL-2019-0006","DOIUrl":"https://doi.org/10.2217/FNL-2019-0006","url":null,"abstract":"Spinal muscular atrophy (SMA) is a childhood disorder caused by loss of the SMN gene. Pathological hallmarks are spinal cord motor neuron death, neuromuscular junction dysfunction and muscle atrophy. The first SMN genetic therapy was recently approved and other SMN-dependent treatments are not far behind. However, not all SMA patients will reap their maximal benefit due to limited accessibility, high costs and differential effects depending on timing of administration and disease severity. The repurposing of commercially available drugs is an interesting strategy to ensure more rapid and less expensive access to new treatments. In this mini-review, we will discuss the potential and relevance of repositioning drugs currently used for neurodegenerative, neuromuscular and muscle disorders for SMA.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2019-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46899329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Imaging markers of disease progression in multiple system atrophy 多系统萎缩疾病进展的影像学标志物
IF 1.3
Future Neurology Pub Date : 2019-08-01 DOI: 10.2217/fnl-2018-0045
B. Heim, F. Krismer, W. Poewe, K. Seppi
{"title":"Imaging markers of disease progression in multiple system atrophy","authors":"B. Heim, F. Krismer, W. Poewe, K. Seppi","doi":"10.2217/fnl-2018-0045","DOIUrl":"https://doi.org/10.2217/fnl-2018-0045","url":null,"abstract":"Different neuroimaging modalities hold potential as surrogate markers of underlying neurodegeneration in multiple system atrophy (MSA) and may reflect cell loss, altered glucose metabolism, microglial proliferation, astroglial activation, and nigrostriatal denervation. Multiple studies have demonstrated that serial structural and functional imaging studies are capable of demonstrating neurodegeneration in MSA patients quantitatively, which allows sample size estimates based on rates of progression of these neuroimaging markers. This review summarizes recent research findings as a tool to assess longitudinal changes of serial neuroimaging-derived parameters in MSA.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"1 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fnl-2018-0045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41613463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Brivaracetam: a newly approved medication for epilepsy Brivaracetam:一种新批准的治疗癫痫的药物
IF 1.3
Future Neurology Pub Date : 2019-08-01 DOI: 10.2217/FNL-2015-0002
J. Oster
{"title":"Brivaracetam: a newly approved medication for epilepsy","authors":"J. Oster","doi":"10.2217/FNL-2015-0002","DOIUrl":"https://doi.org/10.2217/FNL-2015-0002","url":null,"abstract":"Brivaracetam (BRV) in both the USA and EU was developed as a novel molecule for the adjunctive treatment of partial-onset (focal) seizures in patients ≥16 years of age and as of September 2017 was approved for use as monotherapy in the USA uniquely as an antiseizure medication that may be prescribed without a dose finding uptitration. This article reviews BRV's pharmacology, efficacy, safety and adverse event profiles, along with the relevant and noted regulatory hurdles in the USA and the EU. Available postmarketing data will also be summarized. Approximately 3000 patients were studied over about 9 years in the clinical trial program illustrating that BRV has efficacy at 50–200 mg/day with an acceptable adverse event profile.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2015-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43343447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurological implications of nonfatal strangulation and intimate partner violence 非致命勒死和亲密伴侣暴力的神经学意义
IF 1.3
Future Neurology Pub Date : 2019-08-01 DOI: 10.2217/FNL-2018-0031
K. Monahan, A. Purushotham, A. Biegon
{"title":"Neurological implications of nonfatal strangulation and intimate partner violence","authors":"K. Monahan, A. Purushotham, A. Biegon","doi":"10.2217/FNL-2018-0031","DOIUrl":"https://doi.org/10.2217/FNL-2018-0031","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2018-0031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45663741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
The spectrum of paroxysmal dyskinesias 阵发性运动障碍的频谱
IF 1.3
Future Neurology Pub Date : 2019-08-01 DOI: 10.2217/FNL-2018-0047
R. Manso-Calderón
{"title":"The spectrum of paroxysmal dyskinesias","authors":"R. Manso-Calderón","doi":"10.2217/FNL-2018-0047","DOIUrl":"https://doi.org/10.2217/FNL-2018-0047","url":null,"abstract":"Paroxysmal dyskinesias (PxD) comprise a group of heterogeneous syndromes characterized by recurrent attacks of mainly dystonia and/or chorea, without loss of consciousness. PxD have been classified according to their triggers and duration as paroxysmal kinesigenic dyskinesia, paroxysmal nonkinesigenic dyskinesia and paroxysmal exertion-induced dyskinesia. Of note, the spectrum of genetic and nongenetic conditions underlying PxD is continuously increasing, but not always a phenotype–etiology correlation exists. This creates a challenge in the diagnostic work-up, increased by the fact that most of these episodes are unwitnessed. Furthermore, other paroxysmal disorders, included those of psychogenic origin, should be considered in the differential diagnosis. In this review, some key points for the diagnosis are provided, as well as the appropriate treatment and future approaches discussed.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2018-0047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46167550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Hydrogen, the next neuroprotective agent? 氢,下一个神经保护剂?
IF 1.3
Future Neurology Pub Date : 2019-08-01 DOI: 10.2217/FNL-2019-0002
Adrian Marchidann
{"title":"Hydrogen, the next neuroprotective agent?","authors":"Adrian Marchidann","doi":"10.2217/FNL-2019-0002","DOIUrl":"https://doi.org/10.2217/FNL-2019-0002","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2019-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44132704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fragile X- associated Neuropsychiatric Disorders: A Case Report. 脆性 X 相关神经精神障碍:病例报告。
IF 1.3
Future Neurology Pub Date : 2019-05-01 Epub Date: 2019-05-24 DOI: 10.2217/fnl-2018-0040
Maria Melinda Tan, Jeanne Barbara Dy, Maria Jimena Salcedo-Arellano, Flora Tassone, Randi J Hagerman
{"title":"Fragile X- associated Neuropsychiatric Disorders: A Case Report.","authors":"Maria Melinda Tan, Jeanne Barbara Dy, Maria Jimena Salcedo-Arellano, Flora Tassone, Randi J Hagerman","doi":"10.2217/fnl-2018-0040","DOIUrl":"10.2217/fnl-2018-0040","url":null,"abstract":"<p><p>Mutations in the Fragile X Mental Retardation 1 (<i>FMR1</i>) gene create a spectrum of developmental disorders in children in addition to neurodegenerative problems in older populations. Two types of mutations are recognized in the <i>FMR1</i> gene. The full mutation (>200 CGG repeats) in the <i>FMR1</i> gene leads to Fragile X Syndrome which is the most common inherited cause of intellectual disability and autism, while the premutation (55 to 200 CGG repeats) identified among carriers leads to a range of problems linked to elevated levels of the <i>FMR1</i> mRNA leading to mRNA toxicity and occasionally mildly deficient FMRP levels. Two disorders among premutation carriers have been recognized namely: the Fragile X-associated Primary Ovarian Insufficiency (FXPOI) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Recently, in order to recognize a group of associated disorders commonly found in premutation carriers and extensively reported in co-morbidities studies, a new distinctive name was proposed: Fragile X-associated Neuropsychiatric Disorders (FXAND). This paper will present a case report of a female premutation carrier who has encountered predominantly psychiatric problems, but also chronic pain and sleep disturbances consistent with FXAND.</p>","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":"14 2","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034938/pdf/nihms-1044634.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37670373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathophysiology of migraine: an increasingly complex narrative to 2020 偏头痛的病理生理学:一个日益复杂的叙事到2020年
IF 1.3
Future Neurology Pub Date : 2019-05-01 DOI: 10.2217/FNL-2019-0003
V. Gupta
{"title":"Pathophysiology of migraine: an increasingly complex narrative to 2020","authors":"V. Gupta","doi":"10.2217/FNL-2019-0003","DOIUrl":"https://doi.org/10.2217/FNL-2019-0003","url":null,"abstract":"","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/FNL-2019-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49145547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信